keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#1
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28182730/68ga-dotatate-pet-ct-imaging-of-indeterminate-pulmonary-nodules-and-lung-cancer
#2
Ronald Walker, Stephen Deppen, Gary Smith, Chanjuan Shi, Jonathan Lehman, Jeff Clanton, Brandon Moore, Rena Burns, Eric L Grogan, Pierre P Massion
PURPOSE: 18F-FDG PET/CT is widely used to evaluate indeterminate pulmonary nodules (IPNs). False positive results occur, especially from active granulomatous nodules. A PET-based imaging agent with superior specificity to 18F-FDG for IPNs, is badly needed, especially in areas of endemic granulomatous nodules. Somatostatin receptors (SSTR) are expressed in many malignant cells including small cell and non-small cell lung cancers (NSCLCs). 68Ga-DOTATATE, a positron emitter labeled somatostatin analog, combined with PET/CT imaging, may improve the diagnosis of IPNs over 18F-FDG by reducing false positives...
2017: PloS One
https://www.readbyqxmd.com/read/28181822/oncogenic-osteomalacia-role-of-ga-68-dotanoc-pet-ct-scan-in-identifying-the-culprit-lesion-and-its-management
#3
Deepa Singh, Mudalsha Ravina, Narvesh Kumar, Veeresh Dube, Utham Kumar K, Manish Dixit, Sanjay Gambhir
OBJECTIVES: The aim of this study was to evaluate role of (68)Ga-DOTANOC PET/CT scan in localization of culprit lesion for biopsy and required intervention (surgical excision/radiofrequency ablation) in patients with long standing oncogenic osteomalacia (OOM)/tumor induced osteomalacia (TIO). METHODS: 17 patients (08 male & 09 female) underwent (68)Ga-DOTANOC PET/CT scan. The patients referred with clinical and biochemical evidence of hypophosphatemia and raised Fibroblast Growth Factor-23 (FGF-23)...
February 9, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#4
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28166370/peptide-receptor-radionuclide-treatment-and-131-i-mibg-in-the-management-of-patients-with-metastatic-progressive-phaeochromocytomas-and-paragangliomas
#5
Konstantinos Nastos, Vincent T F Cheung, Christos Toumpanakis, Shaunak Navalkissoor, Anne-Marie Quigley, Martyn Caplin, Bernard Khoo
BACKGROUND AND OBJECTIVES: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive/metastatic PCCs and PGLs. METHODS: Patients with progressive/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998-2013...
February 6, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28166144/retro-orbital-breast-cardiac-skin-and-subcutaneous-metastases-of-neuroendocrine-tumor-from-a-tail-gut-cyst-on-68ga-dotatate-pet-ct-imaging
#6
Emine Acar, Hatice Durak, Sare Kabukcuoğlu, Serap Işiksoy, Gamze Çapa Kaya
Tail gut cysts are rare congenital lesions developing from postanal primitive gut remnants. They are mostly benign but carry a potential of malignant transformation, such as adenocarcinoma, neuroendocrine tumor, adenosquamous carcinoma, and pseudomyxoma peritonei. We present a 39-year-old woman with a neuroendocrine tumor arising within a tail gut cyst. She underwent complete resection in 2011. After 4 years, she was admitted with breast nodules, left proptosis, and gaze difficulties. Ga-DOTATATE PET/CT demonstrated extensive metastases including pelvic, lymph node, adrenal gland, bone, retro-orbital, cardiac, breast, skin, and subcutaneous metastases...
February 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28154019/mib1-index-stratified-assessment-of-dual-tracer-pet-ct-with-68ga-dotatate-and-18f-fdg-and-multimodality-anatomical-imaging-in-metastatic-net-of-unknown-primary-cup-net-scheduled-for-prrt
#7
Nikita Sampathirao, Sandip Basu
AIM: Comparative assessment of dual tracer PET/CT ((68)Ga-DOTATATE and (18)F-FDG) and multimodality anatomical imaging in studying CUP-NETs scheduled for PRRT for: (i) divergence of tracer uptake on dual tracer PET/CT, (ii) detection of primary and (iii) overall lesion detection vis-a-vis tumor proliferation index (Mib1/Ki-67). MATERIALS AND METHODS: Fifty-one patients of CUP-NETs (M:F=25:26, age:22-74 years), histopathologically proven and thoroughly investigated with conventional imaging modalities (USG, CT/ceCT, MRI and EUS, wherever applicable), were retrospective analyzed...
February 2, 2017: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/28138688/twins-in-spirit-part-iv-177-lu-%C3%A2-high%C3%A2-affinity-dotatate-a-promising-new-tracer-for-peptide-receptor-radiotherapy
#8
Claudia Brogsitter, Holger Hartmann, Gerd Wunderlich, Margret Schottelius, Hans-Jürgen Wester, Jörg Kotzerke
AIM: Besides the use of somatostatin analogues, small molecules like sunitinib and everolimus as well as conventional chemotherapy, peptide receptor radiotherapy (PRRT) using radiolabelled somatostatin analogues has gained an important role in the treatment of inoperable, metastasized neuroendocrine tumours (NET). There are various radiotracers in use. Based on our experience with the PET tracer [(68)Ga]DOTA-3-iodo-Tyr(3)-octreotate ([(68)Ga]HA-DOTATATE), a DOTATATE derivative with an increased binding affinity to hsst5, the current retrospective analysis is exploring the therapeutic potential of [(177)Lu]HA-DOTATATE...
January 31, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28127694/accuracy-and-precision-assessment-for-activity-quantification-in-individualized-dosimetry-of-177-lu-dotatate-therapy
#9
Gwennaëlle Marin, Bruno Vanderlinden, Ioannis Karfis, Thomas Guiot, Zena Wimana, Patrick Flamen, Stefaan Vandenberghe
BACKGROUND: In order to obtain a reliable (177)Lu-DOTATATE therapy dosimetry, it is crucial to acquire accurate and precise activity measurements with the radionuclide calibrator, the SPECT/CT camera, and the NaI(Tl) well counter. The aim of this study was to determine, in a clinical context, the accuracy and the precision of their activity quantification over a range of activities and time. Ninety-three (177)Lu sources from the manufacturer were measured in the radionuclide calibrator over 2...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28123260/musculoskeletal-oncogenic-osteomalacia-an-experience-from-a-single-centre-in-south-india
#10
Anil Satyaraddi, Kripa Elizabeth Cherian, Sahana Shetty, Nitin Kapoor, Felix K Jebasingh, Vinoo Mathew Cherian, Julie Hephzibah, Anne Jennifer Prabhu, Nihal Thomas, Thomas V Paul
BACKGROUND: Oncogenic osteomalacia is an acquired form of hypophosphatemic osteomalacia where the tumour resection may lead to cure of the disease. Tumours originating from the musculoskeletal region form an important subgroup of oncogenic osteomalacia. METHODS: This was a retrospective study conducted at a tertiary care centre in south India where we analyzed the hospital records of all the patients with musculoskeletal oncogenic osteomalacia from January 2010-April 2016...
March 2017: Journal of Orthopaedics
https://www.readbyqxmd.com/read/28111117/177lu-dotatate-for-midgut-neuroendocrine-tumours
#11
Talha Khan Burki
No abstract text is available yet for this article.
January 19, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28076709/phase-3-trial-of-177-lu-dotatate-for-midgut-neuroendocrine-tumors
#12
RANDOMIZED CONTROLLED TRIAL
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L Kunz, Matthew H Kulke, Heather Jacene, David Bushnell, Thomas M O'Dorisio, Richard P Baum, Harshad R Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy Hobday, Ebrahim Delpassand, Eric Van Cutsem, Al Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Mora, Jordan Berlin, Enrique Grande, Nicholas Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L Erion, Philippe Ruszniewski, Dik Kwekkeboom, Eric Krenning
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ((177)Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either (177)Lu-Dotatate (116 patients) at a dose of 7...
12, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28072620/fibrous-dysplasia-mimicking-malignancy-on-68ga-dotatate-pet-ct
#13
Georgios Z Papadakis, Corina Millo, Samira M Sadowski, Apostolos H Karantanas, Ulas Bagci, Nicholas J Patronas
Fibrous dysplasia of the bone is a developmental benign skeletal disorder characterized by replacement of normal bone and normal bone marrow with abnormal fibro-osseous tissue. We report on a case of a biopsy-proven fibrous dysplasia lesion in the left temporal bone, with intensely increased activity (SUVmax, 56.7) on Ga-DOTATATE PET/CT. The presented data indicate cell surface overexpression of somatostatin receptors by fibrous dysplastic cells and highlight the need of cautious management of Ga-DOTATATE-avid bone lesions, which could mimic malignancy especially in patients with history of neuroendocrine tumors...
March 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28048806/su-g-iep4-05-experience-with-a-practical-approach-to-the-release-of-radioactive-patients-from-radiation-safety-isolation
#14
R Wendt, W Erwin, A Fisher, S Jones, S Jimenez, F Wong, A Jessop
PURPOSE: The radioactive patient releases of the nuclear medicine department in a large cancer center were analyzed to compare the estimated doses to others to the regulatory limit and institutional targets and to gauge how onerous the patients' instructions were. METHODS: In-house software that implements the NUREG 1556 approach and further considers fellow travelers, children and pregnant women and members of the public following Siegel, et al., is used to calculate release timing and to provide patients with individualized instructions...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28033222/relevant-discordance-between-68ga-dotatate-and-68ga-dotanoc-in-sdhb-related-metastatic-paraganglioma-is-affinity-to-somatostatin-receptor-2-the-key
#15
Ingo Janssen, Katherine I Wolf, Chan H Chui, Corina M Millo, Karel Pacak
Pheochromocytomas/paragangliomas are somatostatin receptor 2-overexpressing tumors. Ga-DOTA-peptide imaging has recently shown excellent results in the detection of metastatic lesions in these tumors. However, currently used Ga-DOTA peptides show different somatostatin receptor affinities. Here, we report the remarkable differences in a patient who was imaged with Ga-DOTANOC and Ga-DOTATATE PET/CT within a 7-month period. The patient presented with a nearly negative Ga-DOTANOC PET/CT scan, whereas on Ga-DOTATATE PET/CT, multiple highly positive lesions were identified...
March 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28033220/18f-fdg-and-68ga-dotatate-pet-ct-in-von-hippel-lindau-disease-associated-retinal-hemangioblastoma
#16
Georgios Z Papadakis, Corina Millo, Inderbir S Jassel, Ulas Bagci, Samira M Sadowski, Apostolos H Karantanas, Nicholas J Patronas
Retinal hemangioblastomas are highly vascular benign tumors that can be encountered either sporadically or within the von Hippel-Lindau (VHL) syndrome. We report a case of a VHL patient with retinal hemangioblastoma who underwent PET/CT scans using F-FDG and Ga-DOTATATE. The tumor showed low-level F-FDG and increased Ga-DOTATATE activity, suggesting cell-surface overexpression of somatostatin receptors. The presented case indicates the clinical applications of somatostatin receptor imaging with Ga-DOTA-conjugated peptides in detection and follow-up of VHL manifestations, screening of asymptomatic gene carriers, and in diagnosis of sporadic retinal hemangioblastomas, which may have similar features on MRI with other retinal tumors...
March 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28033218/avascular-necrosis-of-the-hips-with-increased-activity-on-68ga-dotatate-pet-ct
#17
Georgios Z Papadakis, Corina Millo, Apostolos H Karantanas, Ulas Bagci, Nicholas J Patronas
Prolonged exposure to cortisol is one of the major causes of avascular bone necrosis (AVN). We report on a case of a woman with Cushing syndrome attributed to ectopic adrenocorticotropic hormone-secreting tumor who was evaluated with whole-body PET/CT study using Ga-DOTATATE. The scan showed increased activity by both femoral heads, corresponding to the margins of bilateral AVN seen on MRI. The presented data suggests AVN-induced reactive inflammatory alterations adjacent to the necrotic segment of the bone, which can be effectively targeted using radiolabeled somatostatin (SST) analogs...
March 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28026127/well-differentiated-bronchial-neuroendocrine-tumors-clinical-management-and-outcomes-in-105-patients
#18
Marinos Pericleous, Anna Karpathakis, Christos Toumpanakis, Heather Lumgair, Jonathan Reiner, Laura Marelli, Christina Thirlwell, Martyn E Caplin
INTRODUCTION: Bronchial neuroendocrine tumors (NETs) are rare tumors representing approximately 20%-30% of all neuroendocrine tumors and 2%-3% of all adult lung cancers. Here, they present a large case series of well-differentiated bronchial NETs with the aim of investigating the behavior of these tumors and long-term outcomes. METHODS: A retrospective review was performed of 105 patients with bronchial NETs managed in a tertiary referral center in the period between January 1998 and January 2012...
December 27, 2016: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/28005645/68ga-dotatate-pet-ct-in-primary-hepatic-neuroendocrine-tumor
#19
Arun Kumar Reddy Gorla, Rajender Kumar Basher, Lileshwar Kaman, Amanjit Bal, Anish Bhattacharya, Bhagwant Rai Mittal
Primary neuroendocrine tumors of the liver are a diagnostic challenge. We present a rare case of primary hepatic neuroendocrine tumor in which Ga-DOTATATE PET/CT imaging played an important role in the diagnosis and follow-up.
February 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28005640/early-detection-of-bone-metastasis-in-small-cell-neuroendocrine-carcinoma-of-the-cervix-by-68ga-dotatate-pet-ct-imaging
#20
Andres Damian, Graciela Lago, Susana Rossi, Omar Alonso, Henry Engler
The neuroendocrine small cell carcinoma of the cervix is a rare malignancy that has a poor prognosis due to early lymphatic and hematogenous spread. We herein report a case of a 27- year-old woman who was referred for initial staging of a neuroendocrine small cell carcinoma with previous unremarkable structural imaging. Ga-DOTATATE PET/CT revealed focal uptake at the primary tumor and in a solitary pelvic bone lesion suggestive of metastases that was further confirmed by CT-guided biopsy. Somatostatin receptor PET/CT may be a useful image modality for early detection of metastases to guide treatment in these patients...
March 2017: Clinical Nuclear Medicine
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"